Navigation Links
Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration
Date:12/21/2007

- Additional Data Submitted to FDA for Traditional Approval -

YARDLEY, Pa., Dec. 21 /PRNewswire/ -- Tibotec, Inc. today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the protease inhibitor (PI) PREZISTA(TM) (darunavir) tablets, which seeks traditional approval and an expanded indication to include human immunodeficiency virus (HIV)-1-infected, treatment-naive adults. The application includes 48-week data from two Phase 3 studies, ARTEMIS and TITAN, which were presented at HIV conferences earlier this year, as well as 96-week data from the Phase 2b studies, POWER 1, 2, and 3.

PREZISTA received accelerated approval in June 2006 based on the 24-week analysis of HIV viral load and CD4+ cell counts from the pooled analysis of the TMC114-C213 (POWER 1) and TMC114-C202 (POWER 2) Phase 2b studies. As part of the post-marketing commitment, 48-week data from ongoing Phase 3 studies (ARTEMIS and TITAN) and 96-week data from POWER 1, 2, and 3 are required before the FDA can consider traditional approval for PREZISTA.

PREZISTA, co-administered with 100 mg ritonavir and with other antiretroviral agents, is currently indicated for the treatment of human immunodeficiency virus (HIV) infection in antiretroviral treatment-experienced adult patients, such as those with HIV-1 strains resistant to more than one protease inhibitor.

This indication is based on Week 24 analyses of plasma HIV RNA levels and CD4+ cell counts from two controlled trials of PREZISTA/ritonavir (PREZISTA/r) in combination with other antiretroviral drugs. Both studies were conducted in clinically advanced, treatment-experienced (NRTIs, NNRTIs, and PIs) adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.

The following points should be considered when initiating therapy with PREZISTA/r:

-- Treatment history and, when available, genotypic or phenot
'/>"/>

SOURCE Tibotec, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
2. ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
3. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Indevus Announces Submission of New Drug Application
6. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
7. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
8. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
9. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
10. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
11. Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... MARLBOROUGH, Mass , Dec. 22, 2014 /PRNewswire/ -- ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today issued the following open ... Geert Cauwenbergh , Dr. Med. Sc. ... few days a number of inaccurate statements posted ...
(Date:12/22/2014)... 22, 2014  Eiger BioPharmaceuticals Incorporated announced the ... lonafarnib in patients with chronic hepatitis delta virus ... National Institutes of Health (NIH) Clinical Center in ... randomized, placebo-controlled, dose ascending study evaluated two doses ... mg twice daily for 28 days.  "This proof-of-concept ...
(Date:12/22/2014)... , Dec. 22, 2014  Relmada Therapeutics, Inc. ... for the treatment of chronic pain, announced today ... dosed in a pharmacokinetic and pharmacodynamic study with ... neuropathic pain. Racemic methadone is a ... pain states and substitution therapy in opioid addiction.  ...
Breaking Medicine Technology:RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 2Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 3
... -- The popular business magazine, Inc., has named Hardy ... the preceding three quarters, in spite of the current ... Coast region of California and has been servicing laboratories, ... (Logo:   http://photos.prnewswire.com/prnh/20100817/INC5000LOGO ) (Logo: ...
... Inc. magazine today ranked Comfort Medical Supply, LLC ... annual Inc. 500, an exclusive ranking of the nation,s ... look at the most important segment of the economy—America,s ... Under Armour, Jamba Juice, American Apparel, Oracle, and hundreds ...
Cached Medicine Technology:Hardy Diagnostics Named in Inc. 5000 2Comfort Medical Supply, LLC Ranks No. 461 on the 2010 Inc. 500 with Three-Year Sales Growth of 649% 2
(Date:12/22/2014)... Only weeks following the announcement that Henderson, Nevada ... a battery manufacturer create 29 well-paying jobs in Mojave ... launching in Henderson to deliver yet another win ... sector is going to build a stronger middle class ... works with small businesses that rely on middle class ...
(Date:12/22/2014)... December 22, 2014 In recognition of ... sales to Hero Reward, a local organization that provides ... , Located on a couple hundred acres ... Program offers lodging, world class fishing, hunting, hiking, horseback ... was founded several years ago to support U.S. Service ...
(Date:12/22/2014)... Pasadena sleep apnea dentist, ... apnea. Drowsy drivers are 15 times more likely to ... and some experts believe that sleep-deprived drivers may be ... Unfortunately, millions of Americans may be sleep-deprived without even ... Medicine, about 18 million Americans have sleep apnea, but ...
(Date:12/22/2014)... Texas (PRWEB) December 22, 2014 7,178 ... and bustle of Black Friday shopping and opted instead ... and marketing education company, for their 5th annual “Black ... charged just $7 to attend the 5 hour ... that they promptly donated to support two Central Texas ...
(Date:12/22/2014)... Luxury Linen purveyor Peacock Alley once again ... provide logistics and support for one of Dallas’ largest holiday ... history of giving back to the community in which it ... Drive were Whataburger® and 99.5 The Wolf. , There is ... gifts to children who would otherwise not receive any is ...
Breaking Medicine News(10 mins):Health News:TalkLocal Launches in Henderson Weeks Following New Megafactory, New Jobs Announcement 2Health News:Discount Labels Donates Portion of November Sales to Hero Reward Program 2Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 3Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2
... VPP "STAR" DesignationBROOKS, Ore., April 15 Covanta ... (NYSE: CVA ) and a world ... scale Energy-from-Waste and other renewable energy projects, today ... status in the Oregon Department of Consumer and ...
... 15 A new series of national public service ... their health care by knowing and asking appropriate questions ... today by the U.S. Department of Health and Human ... Advertising Council and actress and health advocate Fran Drescher.The ...
... insomnia as a way to address pain, , , WEDNESDAY, April ... people with cancer has often led to trouble sleeping -- ... in fact, sleep seems to cause those problems rather than ... interventions such as cognitive behavioral therapy aimed at eliminating the ...
... The following is a statement by Joseph A. ... Addiction and Substance Abuse at Columbia University :Congratulations ... Carpenter-Palumbo, Commissioner of the New York State Office of ... Collaborative to Improve Outcomes for New York (ACTION) initiative ...
... NEW YORK, April 15 The impetus for the ... settlement by Quest Diagnostics Inc. was a "qui tam" ... the government revealed today. The qui tam lawsuit provided ... a Quest subsidiary, Nichols Institute Diagnostics Inc. (NID), manufactured ...
... go "Meatless" on MondaysNEW YORK, April 15 With World ... environmental advocates are calling on President Obama to take a ... of his predecessors in office have done. Watch the Meatless ... Roosevelt all instituted national meatless days in order to divert ...
Cached Medicine News:Health News:Covanta Marion Recognized for Health and Safety by Oregon OSHA 2Health News:Covanta Marion Recognized for Health and Safety by Oregon OSHA 3Health News:AHRQ and Ad Council Encourage Consumers to Ask Questions and Get More Involved in Their Health Care 2Health News:AHRQ and Ad Council Encourage Consumers to Ask Questions and Get More Involved in Their Health Care 3Health News:Businessman Exposed Problems With Quest Subsidiary's Blood Test Kits; Led to $302 Million Settlement 2Health News:Businessman Exposed Problems With Quest Subsidiary's Blood Test Kits; Led to $302 Million Settlement 3Health News:Obama Urged to Bring Back National Meatless Program 2
... The XL Advantage delivers higher magnification for ... crisp, true image, even at the highest ... edge clarity and precise color rendition is ... with an anti-reflective coating produce a superior ...
... delivers higher magnification for advanced surgical procedures. ... even at the highest magnification. 3.5x, 4.5x ... precise color rendition is ideal for surgical ... coating produce a superior image. The compact ...
... Advantage delivers higher magnification for advanced surgical ... image, even at the highest magnification. 3.5x, ... and precise color rendition is ideal for ... anti-reflective coating produce a superior image. The ...
... Prismatic loupes are higher ... guarenteeing edge to edge ... rendition., ,Keeler Prismatic loupes ... treated with anti reflective ...
Medicine Products: